IL-9 and Its Receptor Are Predominantly Involved in the Pathogenesis of UC
Overview
Authors
Affiliations
Objective: Several pathogenic roles attributed over the past two decades to either T helper (Th)1 or Th2 cells are increasingly becoming associated with interleukin (IL)-17 and most recently IL-9 signalling. However, the implication of IL-9 in IBD has not been addressed so far.
Design: We investigated the expression of IL-9 and IL-9R by using peripheral blood, biopsies and surgical samples. We addressed the functional role of IL-9 signalling by analysis of downstream effector proteins. Using Caco-2 cell monolayers we followed the effect of IL-9 on wound healing.
Results: IL-9 mRNA expression was significantly increased in inflamed samples from patients with UC as compared with controls. CD3(+) T cells were major IL-9-expressing cells and some polymorphonuclear leucocytes (PMN) also expressed IL-9. IL-9 was co-localised with the key Th9 transcription factors interferon regulatory factor 4 and PU.1. Systemically, IL-9 was abundantly produced by activated peripheral blood lymphocytes, whereas its receptor was overexpressed on gut resident and circulating PMN. IL-9 stimulation of the latter induced IL-8 production in a dose-dependent manner and rendered PMN resistant to apoptosis suggesting a functional role for IL-9R signalling in the propagation of gut inflammation. Furthermore, IL-9R was overexpressed on gut epithelial cells and IL-9 induced STAT5 activation in these cells. Moreover, IL-9 inhibited the growth of Caco-2 epithelial cell monolayers in wound healing experiments.
Conclusions: Our results provide evidence that IL-9 is predominantly involved in the pathogenesis of UC suggesting that targeting IL-9 might become a therapeutic option for patients with UC.
The role of efferocytosis in inflammatory bowel disease.
Liu Y, Li Z, Han Y, Wang Q Front Immunol. 2025; 16:1524058.
PMID: 40040696 PMC: 11876057. DOI: 10.3389/fimmu.2025.1524058.
Jiang Z, Yan M, Qin Y, Liu Z, Duan Y, Wang Y Front Pharmacol. 2024; 15:1485255.
PMID: 39717557 PMC: 11663639. DOI: 10.3389/fphar.2024.1485255.
Th9 and Th17 Cells in Human Ulcerative Colitis-Associated Dysplastic Lesions.
Cui G, Yuan A, Sorbye S, Florholmen J Clin Med Insights Oncol. 2024; 18:11795549241301358.
PMID: 39651422 PMC: 11624539. DOI: 10.1177/11795549241301358.
Fungal influence on immune cells and inflammatory responses in the tumor microenvironment (Review).
Zhang J, Feng Y, Li D, Shi D Oncol Lett. 2024; 29(1):50.
PMID: 39564373 PMC: 11574707. DOI: 10.3892/ol.2024.14796.
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.
Bamias G, Menghini P, Pizarro T, Cominelli F Gut. 2024; 74(4):652-668.
PMID: 39266053 PMC: 11885054. DOI: 10.1136/gutjnl-2024-332504.